These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 22677218

  • 1. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
    Arnold LM, Palmer RH, Gendreau RM, Chen W.
    Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
    [Abstract] [Full Text] [Related]

  • 2. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.
    Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ.
    Pain Pract; 2011; 11(2):120-31. PubMed ID: 20642487
    [Abstract] [Full Text] [Related]

  • 3. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.
    Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y, Courvoisier D, Montagne A, Dayer P, Desmeules JA.
    Pain Physician; 2013; 16(5):E553-62. PubMed ID: 24077206
    [Abstract] [Full Text] [Related]

  • 4. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.
    Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM.
    Pain Med; 2010 Feb; 11(2):180-94. PubMed ID: 20002596
    [Abstract] [Full Text] [Related]

  • 5. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
    Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y.
    Arthritis Rheum; 2010 Sep; 62(9):2745-56. PubMed ID: 20496365
    [Abstract] [Full Text] [Related]

  • 7. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
    Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.
    Clin Ther; 2008 Nov; 30(11):1988-2004. PubMed ID: 19108787
    [Abstract] [Full Text] [Related]

  • 8. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia.
    Arnold LM, Leon T, Whalen E, Barrett J.
    Psychosomatics; 2010 Nov; 51(6):489-97. PubMed ID: 21051680
    [Abstract] [Full Text] [Related]

  • 9. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials.
    Mease PJ, Palmer RH, Wang Y.
    J Clin Rheumatol; 2014 Jun; 20(4):195-202. PubMed ID: 24847745
    [Abstract] [Full Text] [Related]

  • 10. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
    Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG.
    Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S27-35. PubMed ID: 15378666
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial.
    Arnold LM, Hirsch I, Sanders P, Ellis A, Hughes B.
    Arthritis Rheum; 2012 Jul; 64(7):2387-97. PubMed ID: 22275142
    [Abstract] [Full Text] [Related]

  • 12. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
    Isaac MT, Isaac MB, Gallo F, Tournoux A.
    Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
    [Abstract] [Full Text] [Related]

  • 13. Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin.
    Arnold LM, Zlateva G, Sadosky A, Emir B, Whalen E.
    Pain Med; 2011 Feb; 12(2):260-7. PubMed ID: 21266008
    [Abstract] [Full Text] [Related]

  • 14. Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin.
    Pauer L, Atkinson G, Murphy TK, Petersel D, Zeiher B.
    Clin J Pain; 2012 Sep; 28(7):609-14. PubMed ID: 22688598
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.
    Arnold LM, Zhang S, Pangallo BA.
    Clin J Pain; 2012 Sep; 28(9):775-81. PubMed ID: 22971669
    [Abstract] [Full Text] [Related]

  • 16. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia.
    Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U.
    Pain Med; 2007 Sep; 8(8):633-8. PubMed ID: 18028041
    [Abstract] [Full Text] [Related]

  • 17. History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.
    Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, Mannelli P, Patkar AA.
    World J Biol Psychiatry; 2009 Sep; 10(4 Pt 2):435-41. PubMed ID: 19382010
    [Abstract] [Full Text] [Related]

  • 18. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.
    Arnold LM, Bateman L, Palmer RH, Lin Y.
    Pediatr Rheumatol Online J; 2015 Jun 26; 13():27. PubMed ID: 26112278
    [Abstract] [Full Text] [Related]

  • 19. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.
    Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Sharma U, Martin SA, Barrett JA, Haig G.
    J Pain; 2008 Sep 26; 9(9):792-805. PubMed ID: 18524684
    [Abstract] [Full Text] [Related]

  • 20. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun 26; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.